关于食品的风险和益处评估的指导
EFSA journal. European Food Safety Authority
|July 17, 2024
概括
欧洲食品安全局 (EFSA) 更新了其食品风险益处评估 (RBA) 指南,将复杂评估和多种健康影响的新方法纳入其中. 这增强了对食品危害和益处的系统评估,以改善监管决策.
科学领域:
- 食品安全和风险评估工作
- 公共卫生政策和法规.
背景情况:
- 欧洲食品安全局 (EFSA) 科学委员会此前在2010年发布了有关风险效益评估 (RBA) 的指南.
- 科学理解和监管要求不断发展,需要对现有的RBA框架进行更新.
研究的目的:
- 修订和更新2010年EFSA关于食品风险效益评估 (RBA) 的指南.
- 将方法上的进步纳入食品安全评估中,并解决当前的监管需求.
- 为评估涉及多种危险和多样化人口子组的复杂场景提供最新的方法.
主要方法:
- 保留了逐步的RBA方法,同时引入了复杂评估的增强方法.
- 开发了系统的方法来识别,优先考虑和选择危险和有益的食品成分.
- 更新了描述有害和有益影响的方法,包括效果大小测量和剂量反应建模.
- 扩大了风险和收益特征的选择,包括可变性,不确定性,严重程度和排名.
- 包括使用诸如残疾调整寿命年 (DALYs) 和质量调整寿命年 (QALYs) 等指标的指导.
- 提出了整合风险和收益的额外方法,考虑影响的概率和严重程度加权.
主要成果:
- 更新的指南为复杂的风险益处评估提供了更全面的方法,包括多种化学危害和各种健康结果.
- 提供了用于描述有害和有益影响的增强方法,使评估更准确.
- 该指南扩大了整合风险和收益的选择,适应基于价值的判断,并利用DALY和QALY等指标.
- 包括关于报告,解释和传达RBA结果的实用建议,考虑到消费者的观点.
结论:
- 更新的EFSA指南提供了一个更强大,更适应的框架,用于进行食品的风险和益处评估.
- 这些修订有助于对复杂的食品相关风险和益处进行更彻底的评估,支持明智的监管决策.
- 概述了改善RBA结果的沟通策略,旨在提高透明度和消费者理解.
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
01:12Hazard Ratio
109
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
109
01:25Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
01:12Relative Risk
142
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
142